Phase I study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor, in patients with advanced cholangiocarcinoma, urothelial carcinoma and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations

被引：0
|
作者：
Garmezy, B. [1 ]
Borad, M. [2 ]
Lin, C. C. [3 ]
Chen, L. T. [4 ]
Perez, C. A. [5 ]
Kato, S. [6 ]
Tam, B. [7 ]
Severson, P. [8 ]
Quah, C. S. [9 ]
Harding, J. J. [10 ]
机构：
[1] Sarah Cannon Res Inst, Res, Nashville, TN USA
[2] Mayo Clin, Ctr Canc, Oncol Dept, Scottsdale, AZ USA
[3] NTUH Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
[4] Kaohsiung Med Univ, Chung Ho Mem Hosp, Hematol Dept, Kaohsiung, Taiwan
[5] Florida Canc Specialists, Med Oncol, Ft Myers, FL USA
[6] Univ Calif San Diego UCSD, Med Oncol, La Jolla, CA USA
[7] Kinnate Biopharma, Clin Sci, San Diego, CA USA
[8] Kinnate Biopharma Inc, Translat Med, San Diego, CA USA
[9] Kinnate Biopharma, Clin Dev, San Diego, CA USA
[10] Mem Sloan Kettering Evelyn H Lauder Breast Ctr, Med, New York, NY USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1423
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
130P
引用
收藏
页码：S231 / S232
页数：2
相关论文
共 46 条
  • [1] Phase 1/1b study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor (FGFRi), in patients (pts) with advanced cholangiocarcinoma (CCA) and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations
    Harding, J.
    Perez, C.
    Kato, S.
    Sharma, M.
    Garmezy, B.
    Quah, C.
    Tam, B.
    Severson, P.
    ANNALS OF ONCOLOGY, 2023, 34 : S63 - S64
  • [2] Discovery of KIN-3248, An Irreversible, Next Generation FGFR Inhibitor for the Treatment of Advanced Tumors Harboring FGFR2 and/or FGFR3 Gene Alterations
    Tyhonas, John S.
    Arnold, Lee D.
    Cox, Jason M.
    Franovic, Aleksandra
    Gardiner, Elisabeth
    Grandinetti, Kathryn
    Kania, Robert
    Kanouni, Toufike
    Lardy, Matthew
    Li, Chun
    Martin, Eric S.
    Miller, Nichol
    Mohan, Adithi
    Murphy, Eric A.
    Perez, Michelle
    Soroceanu, Liliana
    Timple, Noel
    Uryu, Sean
    Womble, Scott
    Kaldor, Stephen W.
    JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (03) : 1734 - 1746
  • [3] First in human (FIH) phase 1/1b study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor (FGFRi), in patients (pts) with advanced urothelial carcinoma (UC) and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations.
    Garmezy, Benjamin
    Perez, Cesar Augusto
    Kato, Shumei
    Sharma, Manish
    Quah, Cheng Seok
    Tam, Betty
    Severson, Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [4] First in human (FIH) phase 1/1b study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor (FGFRi), in patients (pts) with advanced cholangiocarcinoma (CCA) and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations.
    Harding, James J.
    Perez, Cesar Augusto
    Kato, Shumei
    Sharma, Manish
    Garmezy, Benjamin
    Quah, Cheng Seok
    Tam, Betty
    Severson, Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS637 - TPS637
  • [5] Design and rationale of a first-in-human (FIH) phase 1/1b study evaluating KIN-3248, a next-generation, irreversible (irrev), pan-FGFR inhibitor (FGFRi), in adult patients with solid tumors harboring FGFR2 and/or FGFR3 gene alterations (NCT05242822).
    Goyal, Lipika
    Perez, Cesar Augusto
    Kato, Shumei
    Sharma, Manish
    Garmezy, Benjamin
    Kobayashi, Ken
    Franovic, Aleksandra
    Tam, Betty
    Voong, Cynthia
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [6] Activity of KIN-3248, a next-generation pan-FGFR inhibitor, against acquired FGFR-gatekeeper and molecular-brake drug resistance mutations
    Franovic, Aleksandra
    Mohan, Adithi
    Uryu, Sean
    Wu, Qibiao
    Jiang, Ping
    Miller, Nichol
    Tyhonas, John
    Timple, Noelito
    Severson, Paul
    Kania, Robert
    Murphy, Eric
    Bardeesy, Nabeel
    Martin, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [7] A phase 2 study of JNJ-42756493, a pan-FGFR tyrosine kinase inhibitor, in patients (pts) with metastatic or unresectable urothelial cancer (UC) harboring FGFR gene alterations
    Siefker-Radtke, Arlene O.
    Mellado, Begona
    Decaestecker, Karel
    Burke, John M.
    O'Hagan, Anne
    Avadhani, Anjali Narayan
    Zhong, Bob
    Santiago-Walker, Ademi E.
    De Porre, Peter
    Brookman-May, Sabine
    Garcia-Donas, Jesus
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [8] A phase II study of JNJ-42756493, a pan-FGFR tyrosine kinase inhibitor, in patients with metastatic or unresectable urothelial cancer (UC) harboring FGFR gene alterations
    Siefker-Radtke, Arlene O.
    Mellado, Begona
    Decaestecker, Karel
    Burke, John M.
    O'Hagan, Anne
    Avadhani, Anjali
    Zhong, Bob
    Santiago-Walker, Ademi
    De Porre, Peter
    Brookman-May, Sabine
    Garcia-Donas, Jesus
    CANCER RESEARCH, 2016, 76
  • [9] Anti-tumor activity of infigratinib, a potent and selective inhibitor of FGFR1, FGFR2 and FGFR3, in FGFR fusion-positive cholangiocarcinoma and other solid tumors
    Li, Gary
    Krook, Melanie
    Roychowdhury, Sameek
    Avogadri, Francesca
    Ye, Yining
    Moran, Susan
    CANCER RESEARCH, 2019, 79 (13)
  • [10] Expansion part of phase I study of E7090 in patients with cholangiocarcinoma harboring FGFR2 gene fusion and with gastric cancer harboring FGFR2 gene amplification or FGFR2 protein high expression
    Morizane, Chigusa
    Ueno, Makoto
    Ioka, Tatsuya
    Tajika, Masahiro
    Ikeda, Masafumi
    Yamaguchi, Kensei
    Hara, Hiroki
    Yabusaki, Hiroshi
    Miyamoto, Atsushi
    Iwasa, Satoru
    Muto, Manabu
    Takashima, Tsutomu
    Minashi, Keiko
    Komatsu, Yoshito
    Nishina, Tomohiro
    Nakajima, Takako Eguchi
    Sahara, Takatoshi
    Funasaka, Setsuo
    Yashiro, Masakazu
    Furuse, Junji
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
12345